In a recent article for The Observer I noted that almost all the major drug companies had closed down their neuroscience divisions as evidence for a move away from a 'chemical-based' to a 'circuit-based' approach to treatments.
So to my surprise, a new Nature News article has just appeared discussing the re-launch of pharmaceutical giant Novartis's neuroscience section.
However, as I read the beginning of the article, it seems they are just banking on the fact that they can design drugs good enough to hit individual brain circuits.
Well. Best of luck with that.
|
This Blog AMICOR is a communication instrument of a group of friends primarily interested in health promotion, with a focus on cardiovascular diseases prevention. To contact send a message to achutti@gmail.com http://achutti.blogspot.com
Translate AMICOR contents if you like
Thursday, October 10, 2013
Circuit-based human
Subscribe to:
Post Comments (Atom)
No comments:
Post a Comment